Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Carboplatin"" wg kryterium: Temat


Tytuł:
Treatment of advanced ovarian cancer with carboplatin and paclitaxel in a patient undergoing hemodialysis: Case report and literature review.
Autorzy:
Yang Q; Department of Nephrology, Chinese PLA Strategic Support Force Medical Center, Beijing, p.R. China.
Han E; Department of Nephrology, Chinese PLA Strategic Support Force Medical Center, Beijing, p.R. China.
Xu S; Department of Nephrology, Chinese PLA Strategic Support Force Medical Center, Beijing, p.R. China.
Xu Y; Department of Nephrology, Chinese PLA Strategic Support Force Medical Center, Beijing, p.R. China.
Gao J; Department of Nephrology, Chinese PLA Strategic Support Force Medical Center, Beijing, p.R. China.
Pokaż więcej
Źródło:
Hemodialysis international. International Symposium on Home Hemodialysis [Hemodial Int] 2022 Jul; Vol. 26 (3), pp. E31-E36. Date of Electronic Publication: 2022 May 18.
Typ publikacji:
Case Reports; Journal Article; Review
MeSH Terms:
Carboplatin*/therapeutic use
Ovarian Neoplasms*/drug therapy
Paclitaxel*/therapeutic use
Renal Dialysis*
Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Area Under Curve ; Female ; Humans ; Thrombocytopenia
Czasopismo naukowe
Tytuł:
Effects of adding a neurokinin-1 receptor antagonist to 5 mg olanzapine, a 5-hydroxytryptamine-3 receptor antagonist, and dexamethasone for preventing carboplatin-induced nausea and vomiting: a propensity score-matched analysis.
Autorzy:
Yamamoto S; Department of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu, 501-1194, Japan.
Iihara H; Department of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu, 501-1194, Japan. .; Laboratory of Pharmacy Practice and Social Science, Gifu Pharmaceutical University, 1-25-4 Daigakunishi, Gifu, 501-1196, Japan. .
Uozumi R; Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
Kawazoe H; Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, 1-5-30 Shibakoen, Minato-ku, Tokyo, 105-8512, Japan.; Division of Pharmaceutical Care Sciences, Keio University Graduate School of Pharmaceutical Sciences, 1-5-30 Shibakoen, Minato-ku, Tokyo, 105-8512, Japan.
Tanaka K; Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, Shizuoka, 431-3192, Japan.
Fujita Y; Division of Pharmacy, Gunma Prefectural Cancer Center, 617-1 Takahayashi-nishi, Ohta, Gunma, 373-8550, Japan.
Abe M; Division of Gynecology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.; Department of Obstetrics and Gynecology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, Shizuoka, 431-3192, Japan.
Imai H; Division of Respiratory Medicine, Gunma Prefectural Cancer Center, 617-1, Takahayashi-nishi, Ohta, Gunma, 373-8550, Japan.; Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, 1397-1 Yamane, Hidaka, Saitama, 350-1298, Japan.
Karayama M; Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, Shizuoka, 431-3192, Japan.; Department of Clinical Oncology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, Shizuoka, 431-3192, Japan.
Hayasaki Y; Department of Obstetrics and Gynecology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.
Hirose C; Department of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu, 501-1194, Japan.
Suda T; Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, Shizuoka, 431-3192, Japan.
Nakamura K; Department of Gynecology, Gunma Prefectural Cancer Center, 617-1 Takahayashi-nishi, Ohta, Gunma, 373-8550, Japan.
Suzuki A; Department of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu, 501-1194, Japan.; Laboratory of Pharmacy Practice and Social Science, Gifu Pharmaceutical University, 1-25-4 Daigakunishi, Gifu, 501-1196, Japan.
Ohno Y; Department of Cardiology and Respiratory Medicine, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.
Morishige KI; Department of Obstetrics and Gynecology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.
Inui N; Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, Shizuoka, 431-3192, Japan. .; Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, Shizuoka, 431-3192, Japan. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2022 Mar 23; Vol. 22 (1), pp. 310. Date of Electronic Publication: 2022 Mar 23.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Multicenter Study
MeSH Terms:
Carboplatin*/adverse effects
Nausea*/chemically induced
Nausea*/drug therapy
Nausea*/prevention & control
Neurokinin-1 Receptor Antagonists*/therapeutic use
Serotonin 5-HT3 Receptor Antagonists*/therapeutic use
Vomiting*/chemically induced
Vomiting*/drug therapy
Vomiting*/prevention & control
Dexamethasone/therapeutic use ; Humans ; Olanzapine/therapeutic use ; Propensity Score ; Prospective Studies
Czasopismo naukowe
Tytuł:
Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer.
Autorzy:
Omori S; Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Harada H; Division of Radiation Therapy, Shizuoka Cancer Center, Shizuoka, Japan.
Mori K; Department of Biostatistics, Shizuoka Cancer Center, Shizuoka, Japan.
Hisamatsu Y; Department of Thoracic Medical Oncology, Oita Prefectural Hospital, Oita, Japan.
Tsuboguchi Y; Department of Medical Oncology, Osaka City General Hospital, Osaka, Japan.
Yoshioka H; Department of Thoracic Oncology, Kansai Medical University Hospital, Osaka, Japan.
Morinaga R; Department of Thoracic Medical Oncology, Oita Prefectural Hospital, Oita, Japan.
Daga H; Department of Medical Oncology, Osaka City General Hospital, Osaka, Japan.
Kurata T; Department of Thoracic Oncology, Kansai Medical University Hospital, Osaka, Japan.
Takahashi T; Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. .
Pokaż więcej
Źródło:
Investigational new drugs [Invest New Drugs] 2022 Feb; Vol. 40 (1), pp. 106-114. Date of Electronic Publication: 2021 Sep 08.
Typ publikacji:
Clinical Trial, Phase I; Journal Article; Multicenter Study
MeSH Terms:
Albumins/*therapeutic use
Carboplatin/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*therapy
Chemoradiotherapy/*methods
Lung Neoplasms/*therapy
Paclitaxel/*therapeutic use
Aged ; Aged, 80 and over ; Albumins/administration & dosage ; Albumins/adverse effects ; Albumins/pharmacokinetics ; Antineoplastic Combined Chemotherapy Protocols ; Area Under Curve ; Carboplatin/administration & dosage ; Carboplatin/adverse effects ; Carboplatin/pharmacokinetics ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/pathology ; Chemoradiotherapy/adverse effects ; Dose-Response Relationship, Drug ; Female ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/pathology ; Male ; Neoplasm Staging ; Paclitaxel/administration & dosage ; Paclitaxel/adverse effects ; Paclitaxel/pharmacokinetics ; Prospective Studies
Czasopismo naukowe
Tytuł:
Evaluation of amentoflavone metabolites on PARP-1 inhibition and the potentiation on anti-proliferative effects of carboplatin in A549 cells.
Autorzy:
Wang B; State Key Laboratory of Natural Medicines, Department of TCM Pharmaceuticals, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 210009, People's Republic of China; Nanchang Key Laboratory of Quality Control and Safety Evaluation of TCM, Nanchang Inspection and Testing Center, Nanchang 330012, People's Republic of China.
Hu X; State Key Laboratory of Natural Medicines, Department of TCM Pharmaceuticals, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 210009, People's Republic of China.
Wang R; State Key Laboratory of Natural Medicines, Department of TCM Pharmaceuticals, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 210009, People's Republic of China.
Long H; State Key Laboratory of Natural Medicines, Department of TCM Pharmaceuticals, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 210009, People's Republic of China.
Wang H; State Key Laboratory of Natural Medicines, Department of TCM Pharmaceuticals, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 210009, People's Republic of China. Electronic address: .
Pokaż więcej
Źródło:
Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2022 Jan 15; Vol. 56, pp. 128480. Date of Electronic Publication: 2021 Nov 26.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents/*pharmacology
Biflavonoids/*pharmacology
Carboplatin/*pharmacology
Enzyme Inhibitors/*pharmacology
Poly (ADP-Ribose) Polymerase-1/*antagonists & inhibitors
A549 Cells ; Antineoplastic Agents/chemistry ; Antineoplastic Agents/metabolism ; Biflavonoids/chemistry ; Biflavonoids/metabolism ; Carboplatin/chemistry ; Carboplatin/metabolism ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; Enzyme Inhibitors/chemistry ; Enzyme Inhibitors/metabolism ; Humans ; Molecular Structure ; Poly (ADP-Ribose) Polymerase-1/metabolism ; Structure-Activity Relationship
Czasopismo naukowe
Tytuł:
Ovarian toxicity of carboplatin and paclitaxel in mouse carriers of mutation in BRIP1 tumor suppressor gene.
Autorzy:
Ntemou E; Research Laboratory on Human Reproduction, Université Libre de Bruxelles, Brussels, Belgium.
Vidal PD; Research Laboratory on Human Reproduction, Université Libre de Bruxelles, Brussels, Belgium.
Alexandri C; Research Laboratory on Human Reproduction, Université Libre de Bruxelles, Brussels, Belgium.
Van den Steen G; Research Laboratory on Human Reproduction, Université Libre de Bruxelles, Brussels, Belgium.
Lambertini M; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genoa, Italy.; Department of Medical Oncology, UOC Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Demeestere I; Research Laboratory on Human Reproduction, Université Libre de Bruxelles, Brussels, Belgium. .; Obstetrics and Gynaecology Department, Erasme Hospital, Brussels, Belgium. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2022 Feb 01; Vol. 12 (1), pp. 1658. Date of Electronic Publication: 2022 Feb 01.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Genes, Tumor Suppressor*
Germ-Line Mutation*
Antineoplastic Agents, Phytogenic/*adverse effects
Carboplatin/*adverse effects
Fanconi Anemia Complementation Group Proteins/*genetics
Ovarian Reserve/*drug effects
Paclitaxel/*adverse effects
RNA Helicases/*genetics
Animals ; Antineoplastic Agents, Phytogenic/administration & dosage ; Apoptosis/drug effects ; Apoptosis/genetics ; BRCA1 Protein/genetics ; Breast Neoplasms/genetics ; Carboplatin/administration & dosage ; DNA Breaks, Double-Stranded/drug effects ; DNA Repair/drug effects ; DNA Repair/genetics ; Embryonic Development/drug effects ; Embryonic Development/genetics ; Female ; Fertilization in Vitro/methods ; Heterozygote ; Mice ; Mice, Inbred C57BL ; Mice, Knockout ; Models, Animal ; Ovarian Follicle/drug effects ; Ovarian Follicle/metabolism ; Paclitaxel/administration & dosage
Czasopismo naukowe
Tytuł:
Bevacizumab in combination with paclitaxel and platinum for previously treated advanced thymic epithelial tumors.
Autorzy:
Wang CL; Department of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University, No. 241, West Huaihai Road, Shanghai, 200030, China.
Gao LT; Department of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University, No. 241, West Huaihai Road, Shanghai, 200030, China.
Lyu CX; Department of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University, No. 241, West Huaihai Road, Shanghai, 200030, China.
Zhang Q; Department of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University, No. 241, West Huaihai Road, Shanghai, 200030, China.
Zeng WQ; Department of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University, No. 241, West Huaihai Road, Shanghai, 200030, China.
Fang WT; Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Zhu L; Department of Pathology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Fu XL; Department of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University, No. 241, West Huaihai Road, Shanghai, 200030, China. .
Pokaż więcej
Źródło:
Medical oncology (Northwood, London, England) [Med Oncol] 2022 Jan 04; Vol. 39 (2), pp. 25. Date of Electronic Publication: 2022 Jan 04.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Bevacizumab/*administration & dosage
Carboplatin/*administration & dosage
Neoplasms, Glandular and Epithelial/*drug therapy
Paclitaxel/*administration & dosage
Thymus Neoplasms/*drug therapy
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bevacizumab/adverse effects ; Carboplatin/adverse effects ; Female ; Hematologic Diseases/chemically induced ; Humans ; Male ; Middle Aged ; Paclitaxel/adverse effects ; Retrospective Studies ; Survival Analysis ; Treatment Outcome ; Young Adult
SCR Disease Name:
Thymic epithelial tumor
Czasopismo naukowe
Tytuł:
Aberrant expression of TMEM205 signaling promotes platinum resistance in ovarian cancer: An implication for the antitumor potential of DAP compound.
Autorzy:
Calo CA; Division of Gynecologic Oncology, Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Smith BQ; Division of Gynecologic Oncology, Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Dorayappan KDP; Division of Gynecologic Oncology, Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Saini U; Division of Gynecologic Oncology, Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Lightfoot M; Division of Gynecologic Oncology, Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Wagner V; Division of Gynecologic Oncology, Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Kalaiyarasan D; Division of Gynecologic Oncology, Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Cosgrove C; Division of Gynecologic Oncology, Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Wang QE; Department of Radiation Oncology, Comprehensive Cancer Center, The Ohio State University, USA.
Maxwell GL; Inova Women's Service Line and the Inova Schar Cancer Institute, Falls Church, VA, USA.
Kálai T; Institute of Organic and Medicinal Chemistry, Medical School, University of Pécs, Pécs, Hungary.
Kuppusamy P; Departments of Medicine, Geisel School of Medicine, Dartmouth College, 1 Medical Center Drive, Lebanon, NH 03756, USA.
Cohn DE; Division of Gynecologic Oncology, Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Selvendiran K; Division of Gynecologic Oncology, Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH, USA. Electronic address: .
Pokaż więcej
Źródło:
Gynecologic oncology [Gynecol Oncol] 2022 Jan; Vol. 164 (1), pp. 136-145. Date of Electronic Publication: 2021 Oct 30.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents/*pharmacology
Carboplatin/*pharmacology
Membrane Proteins/*drug effects
Ovarian Neoplasms/*drug therapy
Animals ; Antineoplastic Agents/therapeutic use ; Carboplatin/therapeutic use ; Cell Line, Tumor/drug effects ; Cell Line, Tumor/metabolism ; Disease Models, Animal ; Drug Resistance, Neoplasm/drug effects ; Female ; Humans ; Membrane Proteins/antagonists & inhibitors ; Membrane Proteins/metabolism ; Mice ; Mice, Nude ; Ovarian Neoplasms/metabolism
Czasopismo naukowe
Tytuł:
Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial.
Autorzy:
Rob L; Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic.
Cibula D; First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
Knapp P; Department of Gynaecologic Oncology, Medical University of Bialystok, Bialystok, Poland.
Mallmann P; University Hospital of Cologne, Cologne, Germany.
Klat J; Department of Gynecology and Obstetrics, University Hospital Ostrava and University of Ostrava, Ostrava, Czech Republic.
Minar L; Department of Gynecology and Obstetrics, University Hospital Brno and Masaryk University, Brno, Czech Republic.
Bartos P; Department of Gynecology and Obstetrics, Hospital Novy Jicin Novy Jicin, Novy Jicin, Czech Republic.
Chovanec J; Masaryk Memorial Cancer Institute, Brno, Czech Republic.
Valha P; Department of Gynecology and Obstetrics, Hospital Ceske Budejovice, České Budějovice, Czech Republic.
Pluta M; Department of Obstetrics and Gynecology, 2nd Faculty of Medicine, University Hospital Motol, Prague, Czech Republic.
Novotny Z; Department of Gynecology and Obstetrics, Faculty Hospital Plzen, Plzen, Czech Republic.
Spacek J; Department of Obstetrics and Gynecology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic.
Melichar B; Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic.
Kieszko D; Oncological Center of the Lublin Region, Lublin, Poland.
Fucikova J; Department of Immunology, Charles University, Praha, Czech Republic.; SOTIO a.s, Prague, Czech Republic.
Hrnciarova T; First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.; SOTIO a.s, Prague, Czech Republic.
Korolkiewicz RP; SOTIO a.s, Prague, Czech Republic.
Hraska M; SOTIO a.s, Prague, Czech Republic .
Bartunkova J; SOTIO a.s, Prague, Czech Republic.
Spisek R; SOTIO a.s, Prague, Czech Republic .
Pokaż więcej
Źródło:
Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Jan; Vol. 10 (1).
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carboplatin/*therapeutic use
Carcinoma, Ovarian Epithelial/*drug therapy
Dendritic Cells/*immunology
Immunotherapy/*methods
Paclitaxel/*therapeutic use
Acetylcysteine/analogs & derivatives ; Adolescent ; Adult ; Aged ; Aged, 80 and over ; Animals ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Carboplatin/pharmacology ; Female ; Humans ; Mice ; Middle Aged ; Paclitaxel/pharmacology ; Young Adult
Czasopismo naukowe
Tytuł:
Prodrug-based nano-delivery strategy to improve the antitumor ability of carboplatin in vivo and in vitro .
Autorzy:
Lang T; Department of Pharmaceutics, Yantai University, Yantai, PR China.; Department of Pharmaceutics, Binzhou Medical University, Yantai, PR China.
Li N; Department of Pharmaceutics, Yantai University, Yantai, PR China.
Zhang J; Department of Pharmaceutics, Binzhou Medical University, Yantai, PR China.
Li Y; Key Laboratory of Nanomedicine & Advanced Preparations, Yantai Institute of Materia Medica, Yantai, PR China.
Rong R; Key Laboratory of Nanomedicine & Advanced Preparations, Yantai Institute of Materia Medica, Yantai, PR China.
Fu Y; Department of Pharmaceutics, Yantai University, Yantai, PR China.; Key Laboratory of Nanomedicine & Advanced Preparations, Yantai Institute of Materia Medica, Yantai, PR China.
Pokaż więcej
Źródło:
Drug delivery [Drug Deliv] 2021 Dec; Vol. 28 (1), pp. 1272-1280.
Typ publikacji:
Journal Article
MeSH Terms:
Carboplatin/*chemistry
Carboplatin/*pharmacology
Nanoparticles/*chemistry
Prodrugs/*chemistry
Prodrugs/*pharmacology
Animals ; Carboplatin/administration & dosage ; Carboplatin/pharmacokinetics ; Cell Line, Tumor ; Cell Survival ; Chemistry, Pharmaceutical ; Drug Carriers/chemistry ; Drug Liberation ; Female ; Mice ; Mice, Nude ; Micelles ; Particle Size ; Polyethylene Glycols/chemistry ; Prodrugs/administration & dosage ; Prodrugs/pharmacokinetics ; Random Allocation ; Solubility
Czasopismo naukowe
Tytuł:
Investigation of the effects of mTOR inhibitors rapamycin and everolimus in combination with carboplatin on canine malignant melanoma cells.
Autorzy:
Bernard S; Department of Clinical Studies, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada.
Poon AC; Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada.
Tam PM; Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada.
Mutsaers AJ; Department of Clinical Studies, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada. .; Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada. .
Pokaż więcej
Źródło:
BMC veterinary research [BMC Vet Res] 2021 Dec 11; Vol. 17 (1), pp. 382. Date of Electronic Publication: 2021 Dec 11.
Typ publikacji:
Journal Article
MeSH Terms:
Carboplatin*/pharmacology
Carboplatin*/therapeutic use
Dog Diseases*/drug therapy
Everolimus*/pharmacology
Everolimus*/therapeutic use
Melanoma*/drug therapy
Melanoma*/veterinary
Sirolimus*/pharmacology
Sirolimus*/therapeutic use
Animals ; Apoptosis/drug effects ; Cell Line ; Cell Survival/drug effects ; Dogs ; Drug Therapy, Combination/veterinary ; Glycolysis/drug effects ; MTOR Inhibitors/pharmacology
Czasopismo naukowe
Tytuł:
Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer.
Autorzy:
Huang D; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Chowdhury S; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Wang H; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Savage SR; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA.
Ivey RG; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Kennedy JJ; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Whiteaker JR; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Lin C; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Hou X; Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Oberg AL; Department of Quantitative Health Sciences, Division of Computational Biology, Mayo Clinic, Rochester, MN 55905, USA.
Larson MC; Department of Quantitative Health Sciences, Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN 55905, USA.
Eskandari N; Division of Hematology and Oncology, Department of Medicine, University of Illinois, Chicago, IL 60612, USA.
Delisi DA; Division of Hematology and Oncology, Department of Medicine, University of Illinois, Chicago, IL 60612, USA.
Gentile S; Division of Hematology and Oncology, Department of Medicine, University of Illinois, Chicago, IL 60612, USA.
Huntoon CJ; Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Voytovich UJ; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Shire ZJ; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Yu Q; Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.
Gygi SP; Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.
Hoofnagle AN; Department of Lab Medicine, University of Washington, Seattle, WA 98195, USA.
Herbert ZT; Molecular Biology Core Facilities, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Lorentzen TD; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Calinawan A; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Karnitz LM; Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Weroha SJ; Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Kaufmann SH; Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Zhang B; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA.
Wang P; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Birrer MJ; University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Paulovich AG; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Pokaż więcej
Źródło:
Cell reports. Medicine [Cell Rep Med] 2021 Dec 21; Vol. 2 (12), pp. 100471. Date of Electronic Publication: 2021 Dec 21 (Print Publication: 2021).
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms:
Genomics*
Molecular Targeted Therapy*
Carboplatin/*therapeutic use
Carnitine O-Palmitoyltransferase/*metabolism
Cystadenocarcinoma, Serous/*metabolism
Cystadenocarcinoma, Serous/*pathology
Ovarian Neoplasms/*metabolism
Ovarian Neoplasms/*pathology
Acetyl-CoA Carboxylase/genetics ; Acetyl-CoA Carboxylase/metabolism ; Animals ; Apoptosis/drug effects ; Carboplatin/pharmacology ; Carnitine O-Palmitoyltransferase/antagonists & inhibitors ; Carnitine O-Palmitoyltransferase/genetics ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cystadenocarcinoma, Serous/drug therapy ; DNA Damage ; Drug Resistance, Neoplasm/drug effects ; Fatty Acids/metabolism ; Female ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Mice, SCID ; Neoplasm Grading ; Ovarian Neoplasms/drug therapy ; Oxidation-Reduction/drug effects ; Oxidative Phosphorylation/drug effects ; Phosphoproteins/metabolism ; Proteomics ; Reactive Oxygen Species/metabolism
Czasopismo naukowe
Tytuł:
First-line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Results of the NEPTUN study.
Autorzy:
Dechow T; Practice for Oncology Ravensburg, Ravensburg, Germany.
Riera-Knorrenschild J; University Hospital Giessen and Marburg GmbH, Marburg, Germany.
Hackanson B; University Medical Center Augsburg, Augsburg, Germany.
Janssen J; Practice for Hematology and Oncology, Westerstede, Germany.
Schulz H; Practice for Internal Oncology and Hematology, Frechen, Germany.
Chiabudini M; Department of Biostatistics, iOMEDICO, Freiburg, Germany.
Fischer von Weikersthal L; Health Center St. Marien GmbH, Amberg, Germany.
Budweiser S; Hospital Rosenheim, Rosenheim, Germany.
Nacke A; Practice for Hematology and Oncology, Remagen, Germany.
Taeuscher D; SRH Wald-Klinikum Gera GmbH, Gera, Germany.
Welslau M; Medical Care Center at Hospital Aschaffenburg GmbH, Aschaffenburg, Germany.
Potthoff K; Medical Department, iOMEDICO, Freiburg, Germany.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2021 Nov; Vol. 10 (22), pp. 8127-8137. Date of Electronic Publication: 2021 Oct 20.
Typ publikacji:
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Albumins/*therapeutic use
Carboplatin/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Lung Neoplasms/*drug therapy
Paclitaxel/*therapeutic use
Adult ; Aged ; Aged, 80 and over ; Albumins/pharmacology ; Carboplatin/pharmacology ; Carcinoma, Non-Small-Cell Lung/pathology ; Female ; Humans ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Paclitaxel/pharmacology ; Prospective Studies
Czasopismo naukowe
Tytuł:
Prospective clinical trial testing COXEN-based gene expression models of chemosensitivity in dogs with spontaneous osteosarcoma.
Autorzy:
Gustafson DL; Flint Animal Cancer Center, Colorado State University, Fort Collins, CO, USA. .; Department of Clinical Sciences, Colorado State University, Fort Collins, CO, USA. .; University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, CO, USA. .
Collins KP; Flint Animal Cancer Center, Colorado State University, Fort Collins, CO, USA.
Fowles JS; Flint Animal Cancer Center, Colorado State University, Fort Collins, CO, USA.
Ehrhart EJ; Flint Animal Cancer Center, Colorado State University, Fort Collins, CO, USA.; Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA.
Weishaar KM; Flint Animal Cancer Center, Colorado State University, Fort Collins, CO, USA.; Department of Clinical Sciences, Colorado State University, Fort Collins, CO, USA.
Das S; Flint Animal Cancer Center, Colorado State University, Fort Collins, CO, USA.
Duval DL; Flint Animal Cancer Center, Colorado State University, Fort Collins, CO, USA.; Department of Clinical Sciences, Colorado State University, Fort Collins, CO, USA.; University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, CO, USA.
Thamm DH; Flint Animal Cancer Center, Colorado State University, Fort Collins, CO, USA.; Department of Clinical Sciences, Colorado State University, Fort Collins, CO, USA.; University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, CO, USA.
Pokaż więcej
Źródło:
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2021 Oct; Vol. 88 (4), pp. 699-712. Date of Electronic Publication: 2021 Jul 14.
Typ publikacji:
Clinical Trial, Veterinary; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Bone Neoplasms/*drug therapy
Carboplatin/*administration & dosage
Doxorubicin/*administration & dosage
Osteosarcoma/*drug therapy
Amputation/veterinary ; Animals ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/pharmacology ; Bone Neoplasms/pathology ; Bone Neoplasms/surgery ; Carboplatin/pharmacology ; Combined Modality Therapy ; Disease Progression ; Dog Diseases ; Dogs ; Doxorubicin/pharmacology ; Female ; Gene Expression Regulation, Neoplastic ; Male ; Osteosarcoma/pathology ; Progression-Free Survival ; Prospective Studies ; Retrospective Studies ; Survival Rate
Czasopismo naukowe
Tytuł:
Dysfunctional activity of classical DNA end-joining renders acquired resistance to carboplatin in human ovarian cancer cells.
Autorzy:
Yoon MJ; Department of Biomedical Science, School of Life Science, CHA University, 335 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, South Korea.
Cha H; Department of Biomedical Science, School of Life Science, CHA University, 335 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, South Korea.
Ahn J; Department of Biochemistry, Research Institute for Basic Medical Science, School of Medicine, CHA University, 335 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, South Korea.
Lee D; Department of Biomedical Science, School of Life Science, CHA University, 335 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, South Korea.
Jeong HS; Department of Biomedical Science, School of Life Science, CHA University, 335 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, South Korea.
Koo HS; Department of Obstetrics and Gynaecology, CHA Bundang Medical Center, CHA University, 335 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, South Korea.
Kang YJ; Department of Biochemistry, Research Institute for Basic Medical Science, School of Medicine, CHA University, 335 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, South Korea; Department of Obstetrics and Gynaecology, CHA Bundang Medical Center, CHA University, 335 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, South Korea. Electronic address: .
Pokaż więcej
Źródło:
Cancer letters [Cancer Lett] 2021 Nov 01; Vol. 520, pp. 267-280. Date of Electronic Publication: 2021 Aug 08.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carboplatin/*pharmacology
Ovarian Neoplasms/*drug therapy
Receptors, Androgen/*genetics
ATP Binding Cassette Transporter, Subfamily B/genetics ; Carboplatin/adverse effects ; Cell Line, Tumor ; DNA Damage/drug effects ; DNA End-Joining Repair/drug effects ; Drug Resistance, Neoplasm/genetics ; Female ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Ovarian Neoplasms/genetics ; Ovarian Neoplasms/pathology
Czasopismo naukowe
Tytuł:
Carboplatin- and Etoposide-Loaded Lactoferrin Protein Nanoparticles for Targeting Cancer Stem Cells in Retinoblastoma In Vitro.
Autorzy:
Narayana RVL; School of Medical Sciences, University of Hyderabad, Hyderabad, India.
Jana P; Department of Biotechnology and Bioinformatics, School of Life Sciences, University of Hyderabad, Hyderabad, India.
Tomar N; Department of Biotechnology and Bioinformatics, School of Life Sciences, University of Hyderabad, Hyderabad, India.
Prabhu V; School of Medical Sciences, University of Hyderabad, Hyderabad, India.
Nair RM; School of Medical Sciences, University of Hyderabad, Hyderabad, India.; Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States.
Manukonda R; School of Medical Sciences, University of Hyderabad, Hyderabad, India.
Kaliki S; The Operation Eyesight Universal Institute for Eye Cancer, L V Prasad Eye Institute, Hyderabad, India.; Ophthalmic Pathology Laboratory, L V Prasad Eye Institute, Hyderabad, India.
Coupland SE; Liverpool Ocular Oncology Research Group, Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology (ISMIB), University of Liverpool, Liverpool, United Kingdom.; Liverpool Clinical Laboratories, Liverpool University Hospitals Foundation Trust, Liverpool, United Kingdom.
Alexander J; Liverpool Ocular Oncology Research Group, Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology (ISMIB), University of Liverpool, Liverpool, United Kingdom.; School of Biological Sciences, Brambell Laboratories, Bangor University, Bangor, United Kingdom.
Kalirai H; Liverpool Ocular Oncology Research Group, Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology (ISMIB), University of Liverpool, Liverpool, United Kingdom.; Liverpool Clinical Laboratories, Liverpool University Hospitals Foundation Trust, Liverpool, United Kingdom.
Kondapi AK; Department of Biotechnology and Bioinformatics, School of Life Sciences, University of Hyderabad, Hyderabad, India.
Vemuganti GK; School of Medical Sciences, University of Hyderabad, Hyderabad, India.
Pokaż więcej
Źródło:
Investigative ophthalmology & visual science [Invest Ophthalmol Vis Sci] 2021 Nov 01; Vol. 62 (14), pp. 13.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carboplatin/*pharmacology
Etoposide/*pharmacology
Lactoferrin/*chemistry
Nanoparticles/*chemistry
Neoplastic Stem Cells/*drug effects
Retinal Neoplasms/*drug therapy
Retinoblastoma/*drug therapy
Antineoplastic Agents/pharmacokinetics ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents, Phytogenic/pharmacokinetics ; Antineoplastic Agents, Phytogenic/pharmacology ; Biological Availability ; Carboplatin/pharmacokinetics ; Chromatography, High Pressure Liquid ; Culture Media ; Drug Carriers/chemistry ; Drug Delivery Systems ; Etoposide/pharmacokinetics ; Flow Cytometry ; Humans ; Microscopy, Confocal ; Microscopy, Electron, Transmission ; Neoplastic Stem Cells/metabolism ; Neoplastic Stem Cells/pathology ; Retinal Neoplasms/metabolism ; Retinal Neoplasms/pathology ; Retinoblastoma/metabolism ; Retinoblastoma/pathology ; Spectroscopy, Fourier Transform Infrared
Czasopismo naukowe
Tytuł:
The efficacy and safety of first-line treatment in cisplatin-ineligible advanced upper tract urothelial carcinoma patients: a comparison of PD-1 inhibitor and carboplatin plus gemcitabine chemotherapy.
Autorzy:
Huang J; Department of Urology, Ren Ji Hospitlal, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Su R; Department of Urology, Ren Ji Hospitlal, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Chen Z; Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Jiang S; Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Chen M; Department of Urology, Xiangya Hospital, Central South University, Changsha, China.
Yuan Y; Department of Urology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Hu H; Department of Urology, The second hospital of Tianjin medical university, Tianjin, China.
Fu C; Department of Urology, Quanzhou First Hospital affiliated to Fujian Medical University, Quanzhou, China.
Huang Z; Department of Urology, Quanzhou First Hospital affiliated to Fujian Medical University, Quanzhou, China.
Wang Z; The Department of Urology, The Second Affiliated Hospital of Nantong University, Nantong, China.
Zheng B; The Department of Urology, The Second Affiliated Hospital of Nantong University, Nantong, China.
Li C; The Department of Urology, AnHui NO. 2 Provincial People Hospital, Hefei, China.
Wang Z; Department of Pathology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Bao Y; Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Cai M; Department of Urology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Guo J; Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Wei Q; Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Xue W; Department of Urology, Ren Ji Hospitlal, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Pokaż więcej
Źródło:
Oncoimmunology [Oncoimmunology] 2022 Sep 17; Vol. 11 (1), pp. 2124691. Date of Electronic Publication: 2022 Sep 17 (Print Publication: 2022).
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Transitional Cell*/drug therapy
Carcinoma, Transitional Cell*/pathology
Urinary Bladder Neoplasms*/drug therapy
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carboplatin/adverse effects ; Cisplatin/adverse effects ; Deoxycytidine/analogs & derivatives ; Humans ; Immune Checkpoint Inhibitors ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Repurposing FDA-approved drugs against the toxicity of platinum-based anticancer drugs.
Autorzy:
Famurewa AC; Department of Medical Biochemistry, Faculty of Basic Medical Sciences, College of Medicine, Alex Ekwueme Federal University, Ndufu-Alike lkwo, Nigeria. Electronic address: .
Mukherjee AG; Department of Biomedical Sciences, School of Bio-Sciences and Technology, Vellore Institute of Technology (VIT), Vellore, Tamil Nadu 632014, India.
Wanjari UR; Department of Biomedical Sciences, School of Bio-Sciences and Technology, Vellore Institute of Technology (VIT), Vellore, Tamil Nadu 632014, India.
Sukumar A; Department of Integrative Biology, School of Bio-Sciences and Technology, Vellore Institute of Technology (VIT), Vellore, Tamil Nadu 632014, India.
Murali R; Department of Biomedical Sciences, School of Bio-Sciences and Technology, Vellore Institute of Technology (VIT), Vellore, Tamil Nadu 632014, India.
Renu K; Centre of Molecular Medicine and Diagnostics (COMManD), Department of Biochemistry, Saveetha Dental College & Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, 600077, Tamil Nadu, India.
Vellingiri B; Human Molecular Cytogenetics and Stem Cell Laboratory, Department of Human Genetics and Molecular Biology, Bharathiar University, Coimbatore 641 046, Tamil Nadu, India.
Dey A; Department of Life Sciences, Presidency University, Kolkata, West Bengal 700073, India.
Valsala Gopalakrishnan A; Department of Biomedical Sciences, School of Bio-Sciences and Technology, Vellore Institute of Technology (VIT), Vellore, Tamil Nadu 632014, India. Electronic address: .
Pokaż więcej
Źródło:
Life sciences [Life Sci] 2022 Sep 15; Vol. 305, pp. 120789. Date of Electronic Publication: 2022 Jul 09.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Antineoplastic Agents*/toxicity
Organoplatinum Compounds*/pharmacology
Carboplatin/pharmacology ; Cisplatin/pharmacology ; Drug Repositioning
Czasopismo naukowe
Tytuł:
Prognostic impact of adding bevacizumab to carboplatin and paclitaxel for recurrent, persistent, or metastatic cervical cancer.
Autorzy:
Yasunaga M; Department of Gynecology and Obstetrics, Kyushu University Hospital, Fukuoka, Japan. Electronic address: .
Yahata H; Department of Gynecology and Obstetrics, Kyushu University Hospital, Fukuoka, Japan.
Okugawa K; Department of Gynecology and Obstetrics, Kyushu University Hospital, Fukuoka, Japan.
Shimokawa M; Department of Biostatistics, Graduate School of Medicine, Yamaguchi University, Yamaguchi, Japan.
Maeda Y; Department of Gynecology and Obstetrics, Kyushu University Hospital, Fukuoka, Japan.
Hori E; Department of Gynecology and Obstetrics, Kyushu University Hospital, Fukuoka, Japan.
Kodama K; Department of Gynecology and Obstetrics, Kyushu University Hospital, Fukuoka, Japan.
Yagi H; Department of Gynecology and Obstetrics, Kyushu University Hospital, Fukuoka, Japan.
Ohgami T; Department of Gynecology and Obstetrics, Kyushu University Hospital, Fukuoka, Japan.
Onoyama I; Department of Gynecology and Obstetrics, Kyushu University Hospital, Fukuoka, Japan.
Asanoma K; Department of Gynecology and Obstetrics, Kyushu University Hospital, Fukuoka, Japan.
Kato K; Department of Gynecology and Obstetrics, Kyushu University Hospital, Fukuoka, Japan.
Pokaż więcej
Źródło:
Taiwanese journal of obstetrics & gynecology [Taiwan J Obstet Gynecol] 2022 Sep; Vol. 61 (5), pp. 818-822.
Typ publikacji:
Journal Article
MeSH Terms:
Paclitaxel*
Uterine Cervical Neoplasms*/drug therapy
Uterine Cervical Neoplasms*/pathology
Antineoplastic Combined Chemotherapy Protocols ; Bevacizumab ; Carboplatin ; Female ; Humans ; Prognosis ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Cyclin-Dependent Kinase Subunit 2 (CKS2) as a Prognostic Marker for Stages I-III Invasive Non-Mucinous Lung Adenocarcinoma and Its Role in Affecting Drug Sensitivity.
Autorzy:
Feng J; Department of Pathology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450014, China.; Academy of Medical Sciences, Zhengzhou University, Zhengzhou 450001, China.
Hu M; Department of Pathology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450014, China.; Academy of Medical Sciences, Zhengzhou University, Zhengzhou 450001, China.
Li Z; Department of Pathology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450014, China.; Academy of Medical Sciences, Zhengzhou University, Zhengzhou 450001, China.
Hu G; Department of Pathology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450014, China.
Han Y; Department of Pathology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450014, China.; Academy of Medical Sciences, Zhengzhou University, Zhengzhou 450001, China.
Zhang Y; Department of Pathology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450014, China.
Zhang M; Department of Pathology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450014, China.
Ren J; Department of Pathology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450014, China.
Pokaż więcej
Źródło:
Cells [Cells] 2022 Aug 22; Vol. 11 (16). Date of Electronic Publication: 2022 Aug 22.
Typ publikacji:
Journal Article
MeSH Terms:
Adenocarcinoma of Lung*/drug therapy
Adenocarcinoma of Lung*/genetics
CDC2-CDC28 Kinases*/genetics
CDC2-CDC28 Kinases*/metabolism
Carboplatin ; Carrier Proteins/metabolism ; Cell Cycle Proteins/metabolism ; Gene Expression Regulation, Neoplastic ; Humans ; Paclitaxel ; Prognosis ; Tumor Microenvironment
Czasopismo naukowe
Tytuł:
The Effect and Mechanism of Curcumin Combined with Carboplatin Chemotherapy Promoting on Apoptosis of Lung Cancer HCC827 Cells.
Autorzy:
Huang L; Department of Public Health and Preventive Medicine, Medical School, Jinggangshan University, China.
He X; Thoracic Surgery, First Affiliated Hospital of Nanchang University, China.
Zuo X; Department of Respiratory Medicine, Affiliated Hospital of Jinggangshan University, China.
Pokaż więcej
Źródło:
Journal of immunology research [J Immunol Res] 2022 Aug 08; Vol. 2022, pp. 1932692. Date of Electronic Publication: 2022 Aug 08 (Print Publication: 2022).
Typ publikacji:
Journal Article
MeSH Terms:
Curcumin*/pharmacology
Curcumin*/therapeutic use
Lung Neoplasms*/drug therapy
Lung Neoplasms*/metabolism
Apoptosis ; Carboplatin/pharmacology ; Carboplatin/therapeutic use ; Cell Line, Tumor ; Cell Proliferation ; Epithelial Cell Adhesion Molecule ; Humans ; Lung/metabolism ; RNA, Messenger ; Reactive Oxygen Species ; beta Catenin/genetics ; beta Catenin/metabolism
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies

Prześlij opinię

Twoje opinie są dla nas bardzo ważne i mogą być niezwykle pomocne w pokazaniu nam, gdzie możemy dokonać ulepszeń. Bylibyśmy bardzo wdzięczni za poświęcenie kilku chwil na wypełnienie krótkiego formularza.

Formularz